Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00047645 · ClinicalTrials.gov registry record · Phase 3

A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 study, sponsored by InterMune.

Completed
Registry status
Phase 3
Development phase
330
Enrollment target

NCT00047645: Completed Phase 3 study, sponsored by InterMune.

NCT00047645 is a Phase 3 study that has completed, run by InterMune. The registered enrollment target is 330 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00047645, a Phase 3 study, has completed, sponsored by InterMune.

COMPLETED
Registry status
Phase 3
Development phase
330 participants
Enrollment target

Study Summary

Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group.

Interventions

  • DRUG Interferon-gamma 1b

Trial Details

FieldValue
Enrollment Target 330 participants
Start Date 2000-04
Est. Completion 2002-12
Phase Phase 3
InterMune

11 total trials

What the finished NCT00047645 record still lists

NCT00047645 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which Interferon-gamma 1b is the first listed.

NCT00047645 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00047645 about?

NCT00047645 is a clinical study titled "A Study of the Safety and Efficacy Interferon-Gamma 1b in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b administered by subcutaneous injection; compared to placebo in patients with IPF who are unresponsive to steroids. 330 patients have been enrolled and were assigned to either a IFN-g 1b group or a placebo group...

What is the current status of trial NCT00047645?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2000-04. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00047645?

The interventions under investigation include: Interferon-gamma 1b (DRUG).

Who is sponsoring clinical trial NCT00047645?

This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00047645's enrollment target sits among peer trials

330 1066th of 2000 higher than 927 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00359684 · 330 participants

    Use of Cysteamine in the Treatment of Cystinosis

  • NCT03817502 · 330 participants · Phase 3

    Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

  • NCT03922724 · 330 participants · Phase 2

    Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

  • NCT03932773 · 330 participants · NA

    Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00047645, the US trial registry maintained by the National Library of Medicine. NCT00047645 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.